专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130210762A1 SOLID PHARMACEUTICAL COMPOSITION FOR NEUTRALIZING STOMACH ACID 有权
标题翻译：固定化学药物组合物
公开(公告)号：US20130210762A1
公开(公告)日：2013-08-15
申请号：US13641163
申请日：2011-04-18
申请人： Finn Larsen , Jens Richard Pedersen
发明人： Finn Larsen , Jens Richard Pedersen
IPC分类号： A61K47/02 , A61K31/734
CPC分类号： A61K47/02 , A61K9/0065 , A61K9/2009 , A61K9/205 , A61K31/734 , A61K33/00 , A61K33/06 , A61K33/08 , A61K2300/00
摘要： A pharmaceutical composition including an alkaline metal alginate, an alkaline salt, and less than 10% by weight based on the weight of the alkaline metal alginate of a calcium salt. The pharmaceutical composition is intended for the treatment or prophylaxis of dyspepsia in a mammal.
摘要翻译：一种药物组合物，其包含碱金属藻酸盐，碱性盐，并且基于钙盐的碱金属藻酸盐的重量小于10重量％。药物组合物旨在用于治疗或预防哺乳动物的消化不良。

2. 发明授权

US09186409B2 Solid pharmaceutical composition for neutralizing stomach acid 有权
标题翻译：用于中和胃酸的固体药物组合物
公开(公告)号：US09186409B2
公开(公告)日：2015-11-17
申请号：US13641163
申请日：2011-04-18
申请人： Finn Larsen , Jens Richard Pedersen
发明人： Finn Larsen , Jens Richard Pedersen
IPC分类号： A61K47/02 , A61K31/734 , A61K9/00 , A61K9/20 , A61K33/00 , A61K33/06 , A61K33/08
CPC分类号： A61K47/02 , A61K9/0065 , A61K9/2009 , A61K9/205 , A61K31/734 , A61K33/00 , A61K33/06 , A61K33/08 , A61K2300/00
摘要： A pharmaceutical composition including an alkaline metal alginate, an alkaline salt, and less than 10% by weight based on the weight of the alkaline metal alginate of a calcium salt. The pharmaceutical composition is intended for the treatment or prophylaxis of dyspepsia in a mammal.
摘要翻译：一种药物组合物，其包含碱金属藻酸盐，碱性盐，并且基于钙盐的碱金属藻酸盐的重量小于10重量％。药物组合物旨在用于治疗或预防哺乳动物的消化不良。

3. 发明授权

US08192719B2 Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds 有权
标题翻译：通过口服EP 1572或EP 1573化合物诊断生长激素缺乏症的方法和试剂盒
公开(公告)号：US08192719B2
公开(公告)日：2012-06-05
申请号：US12279805
申请日：2007-02-19
申请人： Finn Larsen
发明人： Finn Larsen
IPC分类号： A61K49/10 , G01N33/74 , G01N33/50 , A61K38/27
CPC分类号： G01N33/74
摘要： A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.
摘要翻译：一种评估人或动物受试者生长激素缺乏症的方法，所述方法包括口服施用受试者EP 1572（式I）或EP 1573（式II），获得受试者的给药后样品，样本中的生长激素，并评估样品中生长激素的水平是否表明受试者的生长激素缺乏。优选地，通过免疫测定来测量样品中的GH水平。还公开了构成诊断试剂盒的试剂盒，其包括：（a）配制用于口服给药的EP 1572或EP 1573; 和（b）用于确定样品中生长激素水平的方法。

4. 发明申请

US20090305300A1 METHODS AND KITS TO DIAGNOSE GROWTH HORMONE DEFICIENCY 有权
标题翻译：诊断生长激素缺陷的方法和工具
公开(公告)号：US20090305300A1
公开(公告)日：2009-12-10
申请号：US12279805
申请日：2007-02-19
申请人： Finn Larsen
发明人： Finn Larsen
IPC分类号： G01N33/53
CPC分类号： G01N33/74
摘要： A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.
摘要翻译：一种评估人或动物受试者生长激素缺乏症的方法，所述方法包括口服施用受试者EP 1572（式I）或EP 1573（式II），获得受试者的给药后样品，样本中的生长激素，并评估样品中生长激素的水平是否表明受试者的生长激素缺乏。优选地，通过免疫测定来测量样品中的GH水平。还公开了构成诊断试剂盒的试剂盒，其包括：（a）配制用于口服给药的EP 1572或EP 1573; 和（b）用于确定样品中生长激素水平的方法。

5. 发明申请

US20060034920A1 Effervescent formulations of oxytocin 审中-公开
标题翻译：催产素泡腾制剂
公开(公告)号：US20060034920A1
公开(公告)日：2006-02-16
申请号：US10527879
申请日：2003-09-19
申请人： Finn Larsen
发明人： Finn Larsen
IPC分类号： A61K38/22 , A61K9/46
CPC分类号： A61K9/2077 , A61K9/0007 , A61K9/0056 , A61K9/1676 , A61K38/095
摘要： An effervescent formulation comprising oxytocin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising oxytocin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the oxytocin. The formulation is used for the induction or augmentation of labour or treatment or prevention of postpartum haemorrhage or treatment of missed abortion or facilitation of lactation.
摘要翻译：包含催产素的泡腾制剂，优选包含含有酸性物质，碱性物质和水溶性隔离剂的多层泡腾微球。包含催产素的泡腾制剂，其中在多层泡腾微球中的溶解在几乎立即起泡之后导致催产素的溶液或均匀分散体。该制剂用于诱导或增加劳动或治疗或预防产后出血或治疗错过的流产或促进哺乳。

6. 发明申请

US20070218131A1 EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN 审中-公开
标题翻译：包含降粘剂的有效配方
公开(公告)号：US20070218131A1
公开(公告)日：2007-09-20
申请号：US10593245
申请日：2005-03-18
申请人： Finn Larsen
发明人： Finn Larsen
IPC分类号： A61K9/46 , A61K38/12
CPC分类号： A61K9/0007 , A61K9/5073 , A61K38/095
摘要： An effervescent formulation comprising desmopressin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising desmopressin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the desmopressin. The formulation is used for treating diabetes insipidus, nocturnal enuresis, postoperative polyuria or polydipsia, nocturia associated with multiple sclerosis, mild to moderate haemophilia or von Willebrand's disease.
摘要翻译：包含去氨加压素的泡腾制剂，优选包含含有酸性物质，碱性物质和水溶性隔离剂的多层泡腾微球。包含去氨加压素的泡腾制剂，其中在多层泡腾微球中的溶解在几乎立即起泡后导致去氨加压素的溶液或均匀分散体。该制剂用于治疗尿崩症，夜间遗尿，术后多尿或烦渴，与多发性硬化相关的夜尿症，轻度至中度血友病或血管性血友病。

7. 发明申请

US20070087054A1 EFFERVESCENT FORMULATIONS OF OXYTOCIN 审中-公开
标题翻译：氧化铁的有效配方
公开(公告)号：US20070087054A1
公开(公告)日：2007-04-19
申请号：US11538775
申请日：2006-10-04
申请人： Finn Larsen
发明人： Finn Larsen
IPC分类号： A61K9/46 , A61K38/11
CPC分类号： A61K9/2077 , A61K9/0007 , A61K9/0056 , A61K9/1676 , A61K38/095
摘要： An effervescent formulation comprising oxytocin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising oxytocin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the oxytocin. The formulations used for the induction or augmentation of labour or treatment or prevention of postpartum haemorrhage or treatment of missed abortion or facilitation of lactation.
摘要翻译：包含催产素的泡腾制剂，优选包含含有酸性物质，碱性物质和水溶性隔离剂的多层泡腾微球。包含催产素的泡腾制剂，其中在多层泡腾微球中的溶解在几乎立即起泡之后导致催产素的溶液或均匀分散体。用于诱导或增加劳动或治疗或预防产后出血或治疗错过流产或促进哺乳的制剂。

8. 发明申请

US20060141032A1 Effervescent formulations comprising apomorphine 审中-公开
标题翻译：包含阿扑吗啡的泡腾制剂
公开(公告)号：US20060141032A1
公开(公告)日：2006-06-29
申请号：US10527924
申请日：2003-09-19
申请人： Finn Larsen
发明人： Finn Larsen
IPC分类号： A61K9/46
CPC分类号： A61K31/485 , A61K9/0007 , A61K9/1611 , A61K9/1617 , A61K9/2009 , A61K9/2013 , A61K9/2018
摘要： An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine. The formulation is used for the treatment of male and female sexual dysfunction.
摘要翻译：包含阿扑吗啡的泡腾制剂，优选包含含有酸性物质，碱性物质和水溶性隔离剂的多层泡腾微球。包含阿扑吗啡的泡腾制剂，其中多层泡腾微球的溶解在几乎立即起泡之后导致阿朴吗啡的溶液或均匀分散体。该制剂用于治疗男性和女性性功能障碍。

9. 发明授权

US09023828B2 Composition comprising at least one alginate for use in treatment and/or prevention of overweight 有权
标题翻译：包含至少一种用于治疗和/或预防超重的藻酸盐的组合物
公开(公告)号：US09023828B2
公开(公告)日：2015-05-05
申请号：US14123714
申请日：2012-06-01
申请人： Finn Larsen , Brian Malm , Jens Steen Olsen
发明人： Finn Larsen , Brian Malm , Jens Steen Olsen
IPC分类号： A61K31/734 , A23L1/0532 , A23L1/29 , A23L1/308
CPC分类号： A61K31/734 , A23L29/256 , A23L33/21 , A23L33/30 , A23L33/40 , A23V2002/00 , A23V2200/00 , A61K9/0065 , A61K9/0095 , A61K47/02 , A61K47/26 , A23V2200/332 , A23V2250/5026
摘要： The present invention relates to a composition in the form of a powder or a viscous paste, and which includes at least one low viscosity alginate having a viscosity of less than about 100 mPaS in a 1 wt % aqueous solution, and at least one high viscosity alginate having a viscosity of more than about 100 mPaS in a 1 wt % aqueous solution. The composition can also include at least one suspending agent. The composition is readily soluble in water such that an aqueous preparation can be prepared without substantive mixing. Also, the aqueous preparation is suitable for use in the treatment and/or prevention of overweight for both therapeutic and non-therapeutic purposes.
摘要翻译：本发明涉及一种粉末形式或粘稠糊剂形式的组合物，其包含至少一种在1wt％水溶液中粘度小于约100mPaS的低粘度藻酸盐，以及至少一种高粘度在1重量％水溶液中粘度大于约100mPaS的藻酸盐。组合物还可以包括至少一种悬浮剂。该组合物易溶于水，使得可以在不实质混合的情况下制备水性制剂。此外，水性制剂适合用于治疗和/或预防治疗和非治疗目的的超重。

10. 发明申请

US20140128342A1 COMPOSITION COMPRISING AT LEAST ONE ALGINATE FOR USE IN TREATMENT AND/OR PREVENTION OF OVERWEIGHT 有权
标题翻译：包含至少一种助剂的组合物用于治疗和/或预防过度
公开(公告)号：US20140128342A1
公开(公告)日：2014-05-08
申请号：US14123714
申请日：2012-06-01
申请人： Finn Larsen , Brian Malm , Jens Steen Olsen
发明人： Finn Larsen , Brian Malm , Jens Steen Olsen
IPC分类号： A61K31/734
CPC分类号： A61K31/734 , A23L29/256 , A23L33/21 , A23L33/30 , A23L33/40 , A23V2002/00 , A23V2200/00 , A61K9/0065 , A61K9/0095 , A61K47/02 , A61K47/26 , A23V2200/332 , A23V2250/5026
摘要： The present invention relates to a composition in the form of a powder or a viscous paste, and which includes at least one low viscosity alginate having a viscosity of less than about 100 mPaS in a 1 wt % aqueous solution, and at least one high viscosity alginate having a viscosity of more than about 100 mPaS in a 1 wt % aqueous solution. The composition can also include at least one suspending agent. The composition is readily soluble in water such that an aqueous preparation can be prepared without substantive mixing. Also, the aqueous preparation is suitable for use in the treatment and/or prevention of overweight for both therapeutic and non-therapeutic purposes.
摘要翻译：本发明涉及一种粉末形式或粘稠糊剂形式的组合物，其包含至少一种在1wt％水溶液中粘度小于约100mPaS的低粘度藻酸盐，以及至少一种高粘度在1重量％水溶液中粘度大于约100mPaS的藻酸盐。组合物还可以包括至少一种悬浮剂。该组合物易溶于水，使得可以在不实质混合的情况下制备水性制剂。此外，水性制剂适合用于治疗和/或预防治疗和非治疗目的的超重。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式